Palatin Technologies (PTN) Projected to Announce Quarterly Earnings on Wednesday

Palatin Technologies (NYSEAMERICAN:PTN) will likely be announcing its Q4 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($1.20) per share and revenue of $1.50 million for the quarter. Investors can check the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, September 18, 2026 at 11:30 AM ET.

Palatin Technologies Stock Down 4.7%

Shares of PTN stock opened at $9.99 on Tuesday. The stock has a 50-day moving average of $9.45 and a 200-day moving average of $15.22. Palatin Technologies has a one year low of $5.61 and a one year high of $31.00.

Institutional Investors Weigh In On Palatin Technologies

Several large investors have recently bought and sold shares of PTN. Bleichroeder LP acquired a new stake in Palatin Technologies in the fourth quarter worth $120,000. Jane Street Group LLC acquired a new position in shares of Palatin Technologies in the 4th quarter valued at $166,000. Millennium Management LLC acquired a new position in shares of Palatin Technologies in the 4th quarter valued at $206,000. Geode Capital Management LLC acquired a new position in shares of Palatin Technologies in the 4th quarter valued at $272,000. Finally, Superstring Capital Management LP bought a new stake in shares of Palatin Technologies in the 4th quarter valued at $522,000. Institutional investors own 11.50% of the company’s stock.

Palatin Technologies Company Profile

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.